Table 2. Cytokine and chemokine changes in the spinal cord following chemotherapy.
| Cytokine and Chemokine | PTX -median (interquartile range) | OXA- median (interquartile range) | Saline- median (interquartile range) |
|---|---|---|---|
| IL-3 | 4.5 (4.1–4.7) | 3.8 (3.5–4.1) | 4.0 (3.8–4.1) |
| IL-1β | 107.6 (72.6–113.0) | 89.4 (85.7–97.6) | 91.1 (74.6–110.3) |
| TNF-α | 145.5 (141.2–162.9) * | 132.5 (128.2–143.3) | 126.1 (120.7–141.2) |
| IFN-γ | 10.3 (9.7–11.3) * | 9.5 (9.0–9.7) | 8.9 (7.9–9.6) |
| IL-2 | 14.8 (13.4–16.4) | 11.6 (9.6–13.3) | 12.9 (10.4–14.8) |
| IL-13 | 173.4 (157.4–220.8) | 141.4 (138.7–162.7) | 165.4 (142.7–187.9) |
| IL-6 | 6.9 (4.8–8.6) | 5.5 (4.9–7.2) | 7.0 (5.4–7.3) |
| IL-1α | 16.7 (13.1–18.0) | 14.5 (10.0–15.5) | 14.5 (11.0–16.1) |
| CCL5 | 4.1 (3.6–4.7) | 3.4 (2.9–3.8) | 3.7 (3.0–4.0) |
| IL-10 | 19.3 (18.5–22.5) | 16.8 (15.2–18.1) | 19.3 (17.8–20.7) |
| IL-17α | 18.3 (17.9–18.5) | 18.1 (16.8–18.6) | 16.8 (15.7–17.93) |
| CCL11 | 193.7 (189.9–201.6) * | 181.6 (165.6–190.6) | 170.4 (155.5–181.6) |
| CCL4 | 17.2 (16.4–18.7) * | 16.1 (14.3–17.5) | 13.2 (10.3–14.3) |
| CCL3 | 9.0 (8.7–9.3) ** | 7.9 (7.5–8.2) | 7.3 (6.7–7.9) |
| IL-12p70 | 33.3 (32.4–39.3) * | 31.9 (27.1–32.9) | 30.8 (27.9–31.2) |
| IL-12p40 | 3.4 (3.2–3.8) | 3.0 (2.9–3.0) | 3.1 (2.9–3.2) |
| CCL2 | 49.5 (47.6–57.3) | 45.6 (45.6–50.5) | 45.5 (41.5–49.5) |
| CXCL1 | 2.6 (2.4–4.4) | 2.3 (2.0–2.4) | 2.6 (1.9–3.6) |
| GM-CSF | 82.1 (81.5–85.9) * | 71.6 (70.2–75.6) | 72.9 (67.4–76.3) |
Bio-plex analysis of cytokine and chemokine profile was carried out in the spinal cord on day 13 post-1st injection of paclitaxel (PTX), oxaliplatin (OXA) or saline. Table showing median and interquartile range of cytokine/chemokine concentrations (pg/ml) in in the spinal cord (n = 5);
* P<0.05,
** P<0.01 indicates significant difference between PTX- and Saline-treatment groups; Kruskal Wallis test followed by Dunn’s multiple comparisons test.